Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NANT Ovarian Cancer Vaccine
- Development stage
- Unknown
- Lead developer
- ImmunityBio
- Modality
- Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Small Molecules, Antibody-Based Therapeutics, Cytokines & Interferons → Recombinant Proteins and Enzymes, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Cell Therapies, Live Vector Vaccines → Live Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
01
Overview
The **NANT Ovarian Cancer Vaccine** is an investigational, multi-modal cancer immunotherapy that combines *metronomic low-dose chemotherapy*, *radiation therapy*, and multifaceted immunotherapy, including natural killer (NK) cell-based technology, IL-15 superagonist (N-803), adenoviral- and yeast-vectored cancer antigen vaccines, and checkpoint inhibitor therapy. Its mechanism centers on reversing the immune-suppressive tumor microenvironment, inducing immunogenic tumor cell death, and enhancing innate and adaptive immune responses to generate durable anti-tumor activity. The vaccine is personalized using molecular and immune profiling and is being developed for multiple solid tumors, including ovarian cancer, under the QUILT trial program. Early data have shown efficacy in diverse advanced cancers with favorable safety[^1^][1][3][5][7][8].
- Brand names
- NANT Ovarian Cancer Vaccine
- Other names
- NANT Cancer VaccineNCV
02
Targets
γc family (Common γ-chain receptor family (IL-2/4/7/9/15/21))CD274 (Programmed cell death protein 1 ligand 1)
Beyond the preview
Go deeper on NANT Ovarian Cancer Vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NANT Ovarian Cancer Vaccine.